Intensive usage of antibiotics in medical practice leads to inevitable emergence of 35 resistant bacterial strains (13). To overcome this problem, regular development and adoption of 36 new antibiotics are required. Among other candidates for novel antimicrobial agents are small 37 polypeptide molecules, the so-called antimicrobial peptides (AMPs) (14) . Natural AMPs have 38 been isolated from different organisms, raging from bacteria to higher eukaryotes. In most cases, 39
AMPs are believed to directly bind to target cell membranes at micromolar concentrations and 40 lead to their functional and/or structural disturbance; this mechanism underlies low probability of 41 bacteria acquiring resistance to AMPs (14) . Interestingly, AMPs are found in natural venoms. In 42 particular, spider venoms may simultaneously contain several dozen AMPs with different 43 structure and consequently variable spectrum of activity (4, 11, 12) . 44
Intracellular parasitic bacteria of the genera Mycoplasma and Chlamydia cause infectious 45 diseases that are susceptible to treatment by antibiotics with varying degrees of success and gain 46 increased medical importance (1, 9). AMPs are able to repress Mycoplasma development in vitro 47 (2). However, active peptide concentrations are usually 0.1-10 µM, corresponding to rather high 48 therapeutic doses. Among major obstacles to successful commercialization of AMPs is the high 49 production cost, although there are initiatives to create competitive technologies (10). 50 Development of efficient methods for AMPs application is highly anticipated. One possibility is 51 AMP gene therapy that may substitute direct application of the peptides (3, 5). Our present work 52 proposes a novel method of AMPs application as gene therapy agents. The method is oriented on 53 tackling intracellular infection caused by Chlamydia. To avoid bio-ethic issues, however, we 54 should indicate that gene therapy of humans is not considered at this point. 55
Antichlamydial and antimycoplasmic effects have been previously demonstrated for the 56 AMP melittin in cell cultures and laboratory animals (mice and chicken) (5-7). Melittin, isolated 57 from the venom of the honey bee Apis mellifera, is one of the most famous and probably the best 58 studied AMP. However, strong hemolytic activity and allergic reactions in humans (8) Table 1 . Several peptides (latarcins Ltc 1, Ltc 3a, Ltc 4b) feature restricted activity profiles 64 being highly effective against bacteria, whereas others (latarcins Ltc 2a, Ltc 5, and cyto-65 insectotoxin CIT 1a) show broad spectrum cytolytic activity, reminiscent of melittin. We decided 66
to check the potencies of L. tarabaevi AMPs against Chlamydia and select for peptides that 67 would be both highly effective against intracellular parasites and not toxic to the host cells. 68
Synthetic genes coding for the six AMPs were produced from oligonucleotides (Table 2 ) 69 by annealing and ligation and cloned into the pBI-EGFP vector (Clontech) at the PvuII site as 70 described earlier (7). The reverse tetracycline-controlled transactivator protein (rtTA) gene was 71 amplified using the vector pTet-On (Clontech) and cloned at the BglII site into the same pBI-72 
